Poster Hall | RheumNow

Register

Poster Hall
Industry Sponsored Posters

AbbVie November Poster Thumb

Long-term Malignancy Risk, Including in Higher CV-Risk RA: a JAKi and TNFi

Save

Sponsored by AbbVie Medical Affairs + Health Impact

Nov 01, 2026

AbbVie Septmeber Postre

Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years

Save

Sponsored by AbbVie Medical Affairs + Health Impact

Sep 01, 2026

More Virtual Posters

AbbVie August Poster

Sponsored by AbbVie Medical Affairs + Health Impact

GCA Flares With a JAKi in the Second Year of SELECT-GCA

Sponsored by AbbVie Medical Affairs + Health Impact

A JAKi After Primary or Secondary TNFi Nonresponse in RA (SELECT-SWITCH)

Sponsored by AbbVie Medical Affairs + Health Impact

Real-World Joint Outcomes With an IL-23i vs TNFi or IL-17i in PsA

AbbVie July Poster

Sponsored by AbbVie Medical Affairs + Health Impact

Real-World Predictors and Early Indicators for IBD in Patients With PsA

Bristol Myers Squibb Eular Poster

Sponsored By Bristol Myers Squibb

Efficacy and safety of deucravacitinib through week 52 in patients with active psoriatic arthritis: impact of concomitant methotrexate use in a pooled analysis of the pivotal phase 3 POETYK PsA trials

UCB Eular Poster Front End Image

Sponsored by UCB

Bimekizumab Treatment Resulted in Rapid Response That Was Associated with Clinically Important Improvements in Patient-Reported Outcomes up to 3 Years in Patients with Psoriatic Arthritis

AbbVie Poster 2026

Sponsored by AbbVie Medical Affairs + Health Impact

Long-Term Efficacy and Safety of an IL-23i Through ~5 Years in PsA (KEEPsAKE 1)

UCB RNL 2026 Poster (2)

Sponsored by UCB

Achieving early clinical response was associated with cumulative benefits on disease impact up to 2 years in patients with active psoriatic arthritis treated with bimekizumab

Sanofi RNL26 Image

Sponsored by Sanofi

Real-world effectiveness of interleukin-6 receptor inhibitors compared to methotrexate in steroid- refractory frail patients with polymyalgia rheumatica

Genentech RNL Poster 2

Sponsored by Genentech

Obinutuzumab Induces Histologic Remission and Deep Kidney Parenchymal B-Cell Depletion in Participants With Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY Trial

Sponsored by UCB

Bimekizumab demonstrates comparable one-year efficacy in male and female patients with axial spondyloarthritis: Results from two phase 3 studies

Amgen Poster Submission (RNL2026)

Sponsored by Amgen

One-year real-world effectiveness with avacopan in granulomatosis with polyangiitis and microscopic polyangiitis in a large healthcare system

Genentech RNL Poster 1

Sponsored By Genentech

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

AbbVie December 15, 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Real-World Remission Over 2 Years With a JAKi in RA

RheumNow Poster 9 Updated Thumbnail

Sponsored by AbbVie Medical Affairs + Health Impact

A JAKi in Giant Cell Arteritis: The Impact of Glucocorticoid Tapering

AbbVIe November Poster Front End Image

Sponsored by AbbVie Medical Affairs + Health Impact

Two-Year Efficacy and Safety Outcomes with JAKi Treatment in Patients with Giant Cell Arteritis

UCB Poster ACR Sponsorship

Sponsored by UCB

Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

AbbVie July 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Real-world switching patterns among patients with PsA receiving first-line advanced therapy

AbbVie July 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Real-world effectiveness in PsA after first-line TNFi: JAKi, IL-17i, or another TNFi

AbbVie July 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Long-term safety of a JAKi across ~17,000 patient-years

AbbVie March 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Real-world outcomes in patients with RA remaining on first-line TNFi

AbbVie March 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Time to first musculoskeletal response of an IL-23i in PsA

AbbVie March 2025

Sponsored by AbbVie Medical Affairs + Health Impact

Long-term maintenance of response of an IL-23i in PsA

Sponsored by UCB

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies

Sponsored by Sanofi

Effectiveness of IL-6 Receptor Inhibitors versus Methotrexate or any Conventional Immunomodulators in Patients with Steroid Refractory Polymyalgia Rheumatica

Sponsored by UCB

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies

Sponsored By Amgen

Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

Sanofi RNL Poster

Sponsored By Sanofi

Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

AbbVie Poster (Sept 2024)

Sponsored by AbbVie Medical Affairs

Safety of a JAKi Across 15,000 Patient-Years of Data

UCB Eular Poster

Sponsored by UCB Pharma Medical Affairs

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Sponsored by UCB Pharma Medical Affairs

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Sponsored by UCB Pharma

Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

RNL2024 Poster Submission - Pfizer

Sponsored by Pfizer

Non-Pharmacologic Interventions for Rheumatoid Arthritis

Sponsored by CorEvitas, LLC. And UCB Pharma

Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry

Remission Poster RNL2024

Sponsored By Amgen

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients With Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

Sponsored by Bristol Myers Squibb

Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

Bimekizumab Poster

Sponsored by UCB

Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

×